BioCentury
ARTICLE | Company News

Keytruda combo gains FDA approval in first-line RCC

April 22, 2019 1:48 PM UTC

FDA approved a BLA for Keytruda pembrolizumab in combination with Inlyta axitinib as a first-line therapy for advanced renal cell carcinoma. The decision, which arrived late Friday, came about two months ahead of the combo's June 20 PDUFA date.

The approval is Keytruda's first in any setting to treat RCC. Merck & Co. Inc. (NYSE:MRK) markets the PD-1 inhibitor to treat several cancer types...

BCIQ Company Profiles

Merck & Co. Inc.